Literature DB >> 25919869

[Osteosarcoma lung metastases. Survival after chemotherapy and surgery].

Germán L Farfalli1, José I Albergo, Pablo A Lobos, David E Smith, Patricia D Streitenberger, María G Pallotta Rodríguez, Luis A Aponte-Tinao.   

Abstract

Five years overall survival in osteosarcoma patients is around 70%, although in patients with metastatic disease it is only 10-30%. The objective of this study was to analyze overall survival and prognostic factors in a group of patients with metastatic osteosarcoma treated with surgical removal of the lung metastases. A retrospective review from our oncology data base revealed 38 patients treated between 1992 and 2006. The mean age at diagnosis was 18 ± 9.4 years (3-45) and mean follow-up was 57 ± 53.8 months (12-231). All patients were treated with chemotherapy and oncologic resection of the primary tumor and surgical removal of the lung metastases. We analyzed overall survival and prognostic factors: age, gender, site, time of metastasis, local recurrences, number of lung metastasis and chemotherapy response (necrosis). Overall survival of the entire series was 29% at 5 years (CI 95%: 14.5-43.5) and 26% at 10 years (CI 95%: 12-40). Significant difference in 5 year overall survival was found between good and bad responders to chemotherapy, 53% (IC 95%: 28-78) vs. 8% (IC 95%: 0-20) (p = 0.0008). No statistically significant relationship between other prognostic factors analyzed was observed. Five and ten years overall survival rates in osteosarcoma patients with lung metastasis treated with chemotherapy and surgically resection is poor. Patients with good response to chemotherapy have better prognosis.

Entities:  

Keywords:  lung metastasis; neoadjuvant chemotherapy; osteosarcoma; surgical resection

Mesh:

Year:  2015        PMID: 25919869

Source DB:  PubMed          Journal:  Medicina (B Aires)        ISSN: 0025-7680            Impact factor:   0.653


  12 in total

Review 1.  Growing Pains: The Need for Engineered Platforms to Study Growth Plate Biology.

Authors:  Aleczandria S Tiffany; Brendan A C Harley
Journal:  Adv Healthc Mater       Date:  2022-08-15       Impact factor: 11.092

2.  Silencing hsa_circRNA_0008035 exerted repressive function on osteosarcoma cell growth and migration by upregulating microRNA-375.

Authors:  Gu Gong; Zhifeng Han; Wenjun Wang; Qinli Xu; Jingzhe Zhang
Journal:  Cell Cycle       Date:  2020-08-11       Impact factor: 4.534

3.  PAK5 overexpression is associated with lung metastasis in osteosarcoma.

Authors:  Kun Han; Yan Zhou; Kuo-Fu Tseng; Haiyan Hu; Kunpeng Li; Yaling Wang; Zhihua Gan; Shuchen Lin; Yongning Sun; Daliu Min
Journal:  Oncol Lett       Date:  2017-12-07       Impact factor: 2.967

4.  miR-541 serves as a prognostic biomarker of osteosarcoma and its regulatory effect on tumor cell proliferation, migration and invasion by targeting TGIF2.

Authors:  Chunlei Liu; Xiuling Yi
Journal:  Diagn Pathol       Date:  2020-07-24       Impact factor: 2.644

5.  A population-based propensity-matched study of regional dissections in patients with metastatic osteosarcoma.

Authors:  Wenjuan Wang; Hongzhi Ding; Zhenyu Sun; Chen Jin; Yanhui Zhu; Xiang Wang
Journal:  J Orthop Surg Res       Date:  2020-03-13       Impact factor: 2.359

6.  Silencing of RIPK4 inhibits epithelial‑mesenchymal transition by inactivating the Wnt/β‑catenin signaling pathway in osteosarcoma.

Authors:  Zhigang Yi; Yanchuan Pu; Ruoyan Gou; Yonggang Chen; Xiaojun Ren; Wenzhong Liu; Ping Dong
Journal:  Mol Med Rep       Date:  2020-01-14       Impact factor: 2.952

7.  LncRNA-ANCR regulates the cell growth of osteosarcoma by interacting with EZH2 and affecting the expression of p21 and p27.

Authors:  Fei Zhang; Hao Peng
Journal:  J Orthop Surg Res       Date:  2017-07-05       Impact factor: 2.359

8.  miRNA-21 inhibition inhibits osteosarcoma cell proliferation by targeting PTEN and regulating the TGF-β1 signaling pathway.

Authors:  Xiaoming Hu; Lihua Li; Yao Lu; Xiangui Yu; Hai Chen; Qingshui Yin; Yu Zhang
Journal:  Oncol Lett       Date:  2018-07-19       Impact factor: 2.967

9.  Simultaneous Bilateral Spontaneous Pneumothorax: A Rare Complication of Osteosarcoma.

Authors:  Usman Tariq; Muhammad Saad Sohail; Zainab Fatima; Amina Khan; Abu Baker Sheikh; Shimron I Bhatti
Journal:  Cureus       Date:  2018-06-05

10.  Knock down of Fas-Associated Protein with Death Domain (FADD) Sensitizes Osteosarcoma to TNFα-induced Cell Death.

Authors:  Mario G Hollomon; LaNisha Patterson; Janice Santiago-O'Farrill; Eugenie S Kleinerman; Nancy Gordon
Journal:  J Cancer       Date:  2020-01-14       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.